Novo Nordisk A/S (NYSE:NVO) Trading Up 5.4% – Time to Buy?

Novo Nordisk A/S (NYSE:NVO) traded up 5.4% on Monday . The company traded as high as $55.42 and last traded at $55.2050. 29,600,859 shares traded hands during trading, an increase of 42% from the average session volume of 20,837,451 shares. The stock had previously closed at $52.39.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill now broadly available across the U.S. through major retail pharmacies and telehealth partners, increasing patient access and distribution reach. Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
• Positive Sentiment: Company is offering self?pay access starting at $149/month for the initial dose, a low cash price that should accelerate uptake and compete on affordability versus injectable GLP?1s. Novo Nordisk to sell Wegovy pill to US self-pay patients starting at $149 per month
• Positive Sentiment: Wegovy is the first oral GLP?1 for obesity (daily pill versus weekly injections), a structural product advantage that can revive growth and shift market dynamics. First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
• Positive Sentiment: Market reaction shows competitive pressure: rivals (e.g., Lilly, Viking) have seen share weakness on the roll?out, suggesting investors expect market share benefits for Novo. Novo Nordisk’s weight-loss pill is available. Here’s why Lilly’s and Viking’s stocks are down.
• Neutral Sentiment: UK regulator is reviewing Novo’s Wegovy pill application with a decision possible by year?end, a potential near?term upside if approved. UK’s pharma regulator could issue decision for Novo’s Wegovy pill by year-end
• Neutral Sentiment: Analysts note China market uncertainty could weigh on sales, but the oral Wegovy launch may help keep global revenue on track—monitor regional rollouts and pricing/coverage. China Market Unsettled, But Novo Nordisk’s Oral Wegovy May Keep Revenue On Track
• Negative Sentiment: Head of U.S. public affairs has left the company, a personnel change that could complicate communications or policy interactions during a high?visibility launch. Exclusive: Novo Nordisk’s US public affairs head leaves company

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NVO. Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. The Goldman Sachs Group dropped their target price on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a report on Friday, November 28th. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Finally, Jefferies Financial Group began coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Price Performance

The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The company’s 50 day simple moving average is $49.08 and its 200 day simple moving average is $55.71. The company has a market capitalization of $246.49 billion, a PE ratio of 13.72 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.79 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. True Wealth Design LLC lifted its holdings in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S during the third quarter valued at about $25,000. Strengthening Families & Communities LLC purchased a new position in Novo Nordisk A/S in the third quarter valued at approximately $30,000. NewSquare Capital LLC boosted its position in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the period. Finally, Allianz SE lifted its position in Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after acquiring an additional 238 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.